GLPBio

PF-573228

Catalog No.: GC11107Purity:>99.50%Synonyms: FAK Inhibitor II, Focal Adhesion Kinase Inhibitor II
PF-573228 is an ATP-competitive focal adhesion kinase (FAK) inhibitor (IC50=4nM).

Products are for research use only. Not for human use. We do not sell to patients.


PF-573228
Cas No.: 869288-64-2
10mM (in 1mL DMSO)In Stock
$33.00
1
1mgIn Stock
$12.00
1
5mgIn Stock
$31.00
1
10mgIn Stock
$50.00
1
25mgIn Stock
$98.00
1
50mgIn Stock
$151.00
1
100mgIn Stock
$245.00
1

Citations

No citations are currently available for this product. Below are selected publications citing GlpBio products.
  • Nature cover
    Nature
    641, 529–536 (2025)
  • Nature cover
    Nature
    628, 630–638 (2024)
  • Nature cover
    Nature
    632, 686–694 (2024)
  • Nature cover
    Nature
    618, 1017–1023 (2023)
  • Nature cover
    Nature
    610, 366–372 (2022)
  • Cell cover
    Cell
    187(9):2288-2304 (2024)
  • Cell cover
    Cell
    183(7):1867-1883 (2020)
  • Science cover
    Science
    388(6745) (2025)
  • Science cover
    Science
    387(6739) (2025)
  • Science cover
    Science
    387(6734) (2025)
  • Cell Research cover
    Cell Research
    35, 97–116 (2025)
  • Cell Research cover
    Cell Research
    34, 683–706 (2024)
  • Cell Research cover
    Cell Research
    33, 273–287 (2023)
  • Cell Research cover
    Cell Research
    33, 546–561 (2023)
  • Cell Research cover
    Cell Research
    33, 904–922 (2023)
  • Cell Research cover
    Cell Research
    31, 1291–1307 (2021)

Description

PF-573228 is an ATP-competitive focal adhesion kinase (FAK) inhibitor (IC50=4nM). PF-573228 binds to the FAK kinase domain and inhibits FAK autophosphorylation at Tyr397. PF-573228 disrupts the formation of the FAK-Src complex and downstream signaling for haptotaxis, cell migration, and focal adhesion turnover. PF-573228 can be used in studies related to tumors (such as small cell lung cancer, endocrine-resistant breast cancer, glioblastoma), cardiac fibrosis, skin fibrosis/hypertrophic scars[1-4].

In vitro, co-treatment of HepG2, Huh7, and MHCC97H cells with PF-573228 and 2.5µM Sorafenib for 1-48 hours inhibited Sorafenib-induced upregulation of FAK phosphorylation at Tyr397. PF-573228 synergized with Sorafenib to reduce HCC cell viability and suppress colony formation[5]. Treatment of H2596 cells, MiaPaca 2 cells, and Capan 1 cells with 1-10µM PF-573228 for 24-72 hours dose-dependently reduced cell viability, induced cell cycle arrest, and increased the proportion of apoptotic cells[6]. Treatment of ARK-1 cells with 10µM PF-573228 for 1 hour reduced FAK phosphorylation levels at Tyr397. Treatment of ARK-1 cell-formed 3D spheroids with 10µM PF-573228 for 48 hours significantly reduced spheroid perimeter, decreased Cyclin D1 levels, and reduced cell migration speed and cumulative migration distance[7].

In vivo, NKG mice bearing subcutaneous xenografts of MGC803-CPZ-OENC or MGC803-CPZ-OE cells reaching approximately 100mm³ received daily intraperitoneal injections of 5mg/kg PF-573228 for 5 days per week for 35 consecutive days. PF-573228 inhibited xenograft tumor growth, with a more pronounced inhibitory effect in the CPZ-OE group compared to the CPZ-OENC group[8]. C57B/6 mice received a single intratracheal instillation of 3U/kg Bleomycin Sulfate to establish a pulmonary fibrosis model, followed by daily intraperitoneal injections of 50mg/kg PF-573228 for 21 consecutive days. PF-573228 reduced lung tissue fibrosis, decreased whole-lung Fibronectin and procollagen-1 protein levels, and reduced α-SMA expression[9]. On day 3 after optic nerve transection, Sprague-Dawley rats received a single intravitreal injection of 25mM PF-573228 (4μL). PF-573228 reduced the density of Fluoro-Gold retrograde-labeled retinal ganglion cells in the retinal ganglion cell layer and decreased the number of surviving injured retinal ganglion cells[10].

References:

[1] Slack-Davis JK, Martin KH, Tilghman RW, et al. Cellular characterization of a novel focal adhesion kinase inhibitor. J Biol Chem. 2007 May 18;282(20):14845-52.

[2] Maher S, Bayachou M, Fu P, et al. Focal adhesion kinase activation is involved in contractile stimulation-induced detrusor muscle contraction in mice. Eur J Pharmacol. 2023 Aug 5;952:175807.

[3] Tsang VSK, Riccio F, Wilson AS, et al. A human iPSC-based neural spheroid platform for modelling glioblastoma infiltration using high-content imaging. Sci Rep. 2025 Dec 13;16(1):1223.

[4] Zhang H, Schaefer A, Wang Y, et al. Gain-of-Function RHOA Mutations Promote Focal Adhesion Kinase Activation and Dependency in Diffuse Gastric Cancer. Cancer Discov. 2020 Feb;10(2):288-305.

[5] Feng J, Ye L, Chen C, et al. RhoE downregulation leads to enhanced cholesterol biosynthesis and sorafenib resistance in hepatocellular carcinoma. J Biol Chem. 2025 Dec;301(12):110918.

[6] Kanteti R, Mirzapoiazova T, Riehm JJ, et al. Focal adhesion kinase a potential therapeutic target for pancreatic cancer and malignant pleural mesothelioma. Cancer Biol Ther. 2018;19(4):316-327.

[7] Lopez-Mejia IC, Pijuan J, Navaridas R, et al. Oxidative stress-induced FAK activation contributes to uterine serous carcinoma aggressiveness. Mol Oncol. 2023;17(1):98-118.

[8] Luo R, Huang W, Wang H, et al. CPZ promotes the proliferation of gastric cancer by activating the Wnt pathway through binding with DVL2. Discover Oncol. 2025;16:2085.

[9] Zhao XK, Cheng Y, Cheng ML, et al. Focal Adhesion Kinase Regulates Fibroblast Migration via Integrin beta-1 and Plays a Central Role in Fibrosis. Sci Rep. 2016 Jan 14;6:19276.

[10] D'Onofrio PM. Integrin Activation and Focal Adhesion Kinase in the Survival and Regeneration of Injured Adult Rat CNS Neurons. MSc Thesis, University of Toronto. 2014.

Protocol

Cell experiment [1]:

Cell lines

H2596 cells (human malignant pleural mesothelioma cell line), MiaPaca 2 cells and Capan 1 cells (human pancreatic ductal adenocarcinoma cell lines)

Preparation Method

H2596, MiaPaca 2 and Capan 1 cells were cultured in RPMI 1640 medium supplemented with 10% FBS, L-glutamine and 1% penicillin-streptomycin at 37°C, 5% CO2. Cells were treated with PF-573228 at 1-10μM for 48 or 72h. After treatment, cell viability, apoptosis, cell cycle was measured.

Reaction Conditions

1-10μM; 24-72h

Applications

PF-573228 decreased cell viability in H2596, MiaPaca 2 and Capan 1 cells in a dose-dependent manner. PF-573228 arrested H2596, MiaPaca 2 and Capan 1 cells in G2/M phase. PF-573228 reduced cleaved PARP levels and decreased Cyclin D1 protein in H2596, MiaPaca 2 and Capan 1 cells. PF-573228 inhibited phosphorylation of FAK at Tyr397 and downstream paxillin phosphorylation. PF-573228 decreased anchorage-independent colony number and colony size in H2596, MiaPaca 2 and Capan 1 cells.
Animal experiment [2]:

Animal models

Male NKG mice (6 weeks old, 18-20g) bearing subcutaneous xenografts of MGC803-CPZ-OENC or MGC803-CPZ-OE gastric cancer cells

Preparation Method

When tumor volume reached ~100mm³, mice were randomly assigned to four groups (CPZ-OENC control, CPZ-OENC+PF-573228, CPZ-OE control, CPZ-OE+PF-573228, n=5 per group). Treatment groups received intraperitoneal injections of 5mg/kg PF-573228 (dissolved in DMSO) 5 days per week for 35 days; control groups received DMSO only. Tumor length and width were measured every 3 days to calculate volume (L×W²/2); mice were euthanized on day 35 and tumors excised for final volume/weight recording.

Dosage form

5mg/kg; i.p.; 5 days/week for 35 days

Applications

PF-573228 inhibited subcutaneous xenograft tumor growth in both MGC803-CPZ-OENC and MGC803-CPZ-OE models. PF-573228 produced a greater reduction in tumor volume and weight in the CPZ-OE group than in the CPZ-OENC group.

References:

[1] Kanteti R, Mirzapoiazova T, Riehm JJ, et al. Focal adhesion kinase a potential therapeutic target for pancreatic cancer and malignant pleural mesothelioma. Cancer Biol Ther. 2018;19(4):316-327.

[2] Luo R, Huang W, Wang H, et al. CPZ promotes the proliferation of gastric cancer by activating the Wnt pathway through binding with DVL2. Discover Oncol. 2025;16:2085.

Product Documents

Purity:>99.50%Appearance:A solid

Chemical Properties

CAS No.
869288-64-2
Synonyms
FAK Inhibitor II, Focal Adhesion Kinase Inhibitor II
Chemical Name
6-[[4-[(3-methylsulfonylphenyl)methylamino]-5-(trifluoromethyl)pyrimidin-2-yl]amino]-3,4-dihydro-1H-quinolin-2-one
SMILES
CS(=O)(=O)C1=CC=CC(=C1)CNC2=NC(=NC=C2C(F)(F)F)NC3=CC4=C(C=C3)NC(=O)CC4
Molecular Formula
C22H20F3N5O3S
Molecular Weight
491.49
Solubility
≥ 166.6mg/mL in DMSO
Storage
Store at -20°C
General tips
Select a suitable solvent according to the product solubility data. Once prepared, aliquot the stock solution to avoid repeated freeze-thaw cycles.
Use stock solutions within 6 months when stored at -80°C or within 1 month when stored at -20°C.
To improve solubility, warm the tube to 37°C and sonicate it for an appropriate period.
Shipping Condition
Evaluation samples are shipped with blue ice. Other available sizes are shipped at room temperature or with blue ice upon request.

CalculatorsMolarity / Dilution / Molecular Weight / Unit Conversion / In Vivo Formulation / Solubility

g/mol

Reviews

Review for PF-573228

Rating: 5
  • 5 Star100%
  • 4 Star0%
  • 3 Star0%
  • 2 Star0%
  • 1 Star0%